Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans.
M.B. Khazaeli(University of Alabama at Birmingham), Kim R. Rogers, Terry Baker, Richard Wheeler(University of Washington Medical Center), Ruby F. Meredith(University of Nebraska Medical Center), Mansoor N. Saleh(Georgia Cancer Specialists), David J. King(AnaBios (United States)), Laquetta Allen, David S. Secher, T.-P. Liu
PubMed
October 15, 1991
Cited by 120
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker
|Nature Biotechnology|1992|465
Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: Report of intergroup study 0034
|International Journal of Radiation Oncology*Biology*Physics|1992|413
Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage
|Science|2020|382
A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody
|Molecular Immunology|1993|243